Darling Ingredients' Rousselot has announced receipt of US patent for StabiCaps gelatin technology
Rousselot, a health brand of Darling Ingredients, has been granted a U.S. Patent and Trademark Office Patent No. UA11795489B2 for its StabiCaps product.
Photo © Shutterstock.com/jovan vitanovski
Rousselot, a health brand of Darling Ingredients (Irving, CA), has been granted a U.S. Patent and Trademark Office Patent No. UA11795489B2, securing the intellectual property rights for StabiCaps, which is a specialized gelatin that improves the formulation and stability of soft gel capsules by addressing crosslinking. The company explains in a press release that crosslinking happens when the soft gels are exposed to specific active compounds or poor storage conditions to cause molecular bonds within the capsule shell that limit or prevent dissolution of the capsule.
“StabiCaps is an essential innovation for soft gel manufacturers because gelatin is a primary ingredient,” said Pierre-Albert Thomas, Rousselot Functional Ingredients Director, in a press release. “With this new patent, soft gel manufacturers in the U.S. can unlock the benefits of StabiCaps gelatin technology to produce high-quality soft gels with longer shelf stability and improved efficacy for customers.”
Magnesium L-threonate, Magtein, earns novel food authorization in the European Union
December 19th 2024According to the announcement, the authorization is also exclusive to AIDP and its partner company and licensee, ThreoTech, meaning that they are the only parties that can market magnesium L-threonate in the EU for a period of five years.
Survey finds a lack of enthusiasm about AI technology among food and beverage consumers
December 12th 2024The survey, commissioned by Ingredient Communications and conducted by SurveyGoo, found that 83% of respondent agreed that companies should declare on product labels when a product has been designed or manufactured with the assistance of AI technology.
Kelker Pharma to launch nutritional support system for GLP-1 medication users that features TriBsyn
December 11th 2024B&D Nutritional Ingredients Inc., an exclusive distribution partner of CarnoSyn Brands and Natural Alternatives International Inc., announced that its customer, Kelker Pharma, will be launching the “first science-backed nutritional support system” for GLP-1 medication users, called Nutrilinq Genesis.
